{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-041082","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.430308+00:00","generated_at":"2026-05-22T04:55:13.034161+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"INmune Bio Q1 net loss narrows to $9.7M; Alzheimer's Phase 2 data expected late June","bullets":["Net loss $9.7M ($0.42 per share) vs $11.0M YoY; R&D expenses down to $7.6M from $8.7M.","Cash $19.3M at March 31; raised $2.1M post-quarter via stock sale; 23.2M shares outstanding.","Top-line results from Phase 2 Alzheimer's trial (MINDFuL) expected in second half of June.","Plans to file BLA for CORDStrom in RDEB in early 2026; partnered with Catapult for manufacturing scale-up.","INKmune Phase I completed, Phase II opened; safety endpoint met; trial expanded to VA Health System."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-041082","json":"https://secwatch.observer/filing/0001213900-25-041082.json","markdown":"https://secwatch.observer/filing/0001213900-25-041082.md","text":"https://secwatch.observer/filing/0001213900-25-041082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025041082/0001213900-25-041082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025041082/ea0241453-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:55:13.034161+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}